XML 68 R49.htm IDEA: XBRL DOCUMENT
v3.22.4

Royalty and Commercial Payment Purchase Agreements - Aronora (Details) $ in Thousands |  | 1 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Apr. 07, 2019 USD ($) item | Sep. 30, 2019 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($)
Agreements |  |  |  |  |
Long-term royalty and commercial payment receivables |  |  | $ 63,683 | $ 69,075 | $ 34,575
Contingent consideration under RPAs and CPPAs |  |  | 75 | 8,075 |
Impairment of long-term royalty receivable |  |  | 0 | $ 0 |
Aronora | Royalty Purchase Agreement |  |  |  |  |
Agreements |  |  |  |  |
Number of drug candidates | item | 5 |  |  |  |
Non-royalties to be received (as a percent) | 10.00% |  |  |  |
Future non-royalty payments to be received (as a percent) | 5.00% |  |  |  |
Multiplier for cumulative amount of consideration paid | item | 2 |  |  |  |
Upfront payment | $ 6,000 |  |  |  |
Threshold amount of cumulative royalties on net sales per product | 250,000 |  |  |  |
Aggregate milestones payments per product | 85,000 |  |  |  |
Long-term royalty and commercial payment receivables | 9,000 |  |  |  |
Contingent consideration under RPAs and CPPAs | 3,000 |  |  |  |
Payments of contingent consideration |  | $ 3,000 |  |  |
Impairment of long-term royalty receivable |  |  | $ 0 |  |
Aronora | Royalty Purchase Agreement | SVB Loan |  |  |  |  |
Agreements |  |  |  |  |
Upfront payment | $ 3,000 |  |  |  |
Aronora | Royalty Purchase Agreement | Bayer Products |  |  |  |  |
Agreements |  |  |  |  |
Number of drug candidates | item | 3 |  |  |  |
Number of drug candidates subject to exclusive license option | item | 1 |  |  |  |
Royalties entity has right to receive (as a percent) | 100.00% |  |  |  |
Non-royalties to be received (as a percent) | 10.00% |  |  |  |
Contingent future cash payment for each product | $ 1,000 |  |  |  |
Potential future cash payments | $ 3,000 |  |  |  |
Aronora | Royalty Purchase Agreement | Non-Bayer Products |  |  |  |  |
Agreements |  |  |  |  |
Number of drug candidates | item | 2 |  |  |  |
Non-royalties to be received (as a percent) | 10.00% |  |  |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of drug candidates subject to exclusive license option. + References No definition available. + Details
Name: | xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of drug candidates under the terms of the agreement. + References No definition available. + Details
Name: | xoma_AgreementDrugCandidatesNumber
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Multiplier used in determining change in payment percentage. + References No definition available. + Details
Name: | xoma_AgreementPaymentPercentageFactor
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements. + References No definition available. + Details
Name: | xoma_ContingentConsiderationUnderPurchaseAgreements
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent future cash payments. + References No definition available. + Details
Name: | xoma_ContingentFutureCashPayments
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of contingent future cash payment for each product. + References No definition available. + Details
Name: | xoma_ContingentFutureCashPaymentsPerProduct
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Threshold amount of cumulative royalties on net sales per product under the terms of the agreement + References No definition available. + Details
Name: | xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets. + References No definition available. + Details
Name: | xoma_ImpairmentOfLongTermRoyaltyReceivable
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Long-term royalty and commercial rights receivables, non current. + References No definition available. + Details
Name: | xoma_LongTermRightsReceivableNonCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum amount of aggregate tiered milestone payments to be made under the terms of the agreement. + References No definition available. + Details
Name: | xoma_MilestonesPaymentsToAggregateAmountOfPerProduct
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments of contingent consideration. + References No definition available. + Details
Name: | xoma_PaymentsOfContingentConsideration
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Purchased percentage of non-royalties on net sales of products. + References No definition available. + Details
Name: | xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid. + References No definition available. + Details
Name: | xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Royalties entity has the right to receive as a percentage. + References No definition available. + Details
Name: | xoma_RoyaltyReceivablePercentageOnNetSales
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow for initial payment under agreement. + References No definition available. + Details
Name: | xoma_UpfrontPayment
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_AronoraIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_BayerProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_NonBayerProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |